New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
DIFFERENCES IN HOST INFILTRATES AMONG LYMPHOMA PATIENTS TREATED WITH ANTI-IDIOTYPE ANTIBODIES - CORRELATION WITH TREATMENT RESPONSE
DIFFERENCES IN HOST INFILTRATES AMONG LYMPHOMA PATIENTS TREATED WITH ANTI-IDIOTYPE ANTIBODIES - CORRELATION WITH TREATMENT RESPONSE JOURNAL OF IMMUNOLOGY Garcia, C. F., Lowder, J., MEEKER, T. C., Bindl, J., Levy, R., Warnke, R. A. 1985; 135 (6): 4252-4260Abstract
To correlate treatment responses with numbers and types of "host cell infiltrates," lymphoid tissues from 10 patients with low-grade B cell malignancies were stained before, during, and after anti-idiotype therapy with a panel of monoclonal antibodies applied to frozen sections. Tissue penetration by the anti-idiotype antibodies was confirmed in five patients by these immunoperoxidase methods. Large numbers of phenotypic T helper cells were the main component of the "host infiltrate" in most patients. Two patients showed a complete and a near-complete clinical remission, four others had partial responses, and four did not respond to therapy. The two patients that developed clinical remission demonstrated the largest number of T cells, T helper cells, TAC+ cells, Leu-7+ cells, and in general the smallest number of proliferating cells as measured by the Ki-67 antibody. Other major differences in host cells were not evident among the patients. These preliminary data suggest that the type and amount of "host infiltrate" in low-grade B cell lymphomas may predict which patients will respond to anti-idiotype therapy.
View details for Web of Science ID A1985AUL1400096
View details for PubMedID 2933460